Canada approves new drug that can slow Alzheimer’s disease

For the first time, Health Canada has approved a new drug that targets the underlying cause of early-onset Alzheimer’s to slow its progression.

Lecanemab, commercially known as Leqembi, has already been approved in other countries.

It works by clearing beta amyloid proteins from the brain. The plaque-like buildup of such proteins is a hallmark of Alzheimer’s.

Health reporter Katherine Ward reports on this new drug – and how it’s opening up new treatment options for patients.

For more info, please go to https://globalnews.ca
Subscribe to Global News Channel HERE: http://bit.ly/20fcXDc
Like Global News on Facebook HERE: http://bit.ly/255GMJQ
Follow Global News on X HERE: http://bit.ly/1Toz8mt
Follow Global News on Instagram HERE: https://bit.ly/2QZaZIB
#health #alzheimers #alzheimersdisease #GlobalNews

mBlip